Abstract
A novel class of 2,3-diaminopyridine bradykinin B1 receptor antagonists is disclosed. Structure-activity relationship studies (SARs) that led to compounds with significantly improved potency and pharmacokinetic properties relative to the lead compound are described.
MeSH terms
-
Aminopyridines / chemistry
-
Aminopyridines / pharmacology*
-
Bradykinin B1 Receptor Antagonists*
-
Drug Design
-
Humans
-
Kinetics
-
Models, Molecular
-
Pyridines / chemical synthesis*
-
Pyridines / pharmacology
-
Structure-Activity Relationship
Substances
-
Aminopyridines
-
Bradykinin B1 Receptor Antagonists
-
Pyridines
-
2,3-diaminopyridine